TY - JOUR
T1 - Correlation of radiographic damage and metabolic syndrome in spondyloarthritis
T2 - A cross-sectional study
AU - Gunawan, Hendra
AU - Mudjanarko, Sony Wibisono
AU - Awalia,
AU - Rahmawati, Lita Diah
AU - Soeroso, Joewono
AU - Pranoto, Agung
N1 - Publisher Copyright:
© 2019 The Authors.
PY - 2019/9
Y1 - 2019/9
N2 - Background: Cardiovascular complication remains the long-term complications in spondyloarthritis (SpA). Previous studies revealed that metabolic syndrome is the risk factor of cardiovascular in SpA patients. Previous studies also revealed that the prevalence of the metabolic syndrome is 34.9– 45.7% in SpA patients. However, previous studies also revealed the controversy of the correlation of SpA’ disease activity with metabolic syndrome. Aim: The aim of the study was to investigate the correlation of SpA’ radiographical damage measured with a modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) score with metabolic syndrome in SpA patients, which routinely visited Rheumatology Outpatient Department in Dr. Soetomo General Hospital. Methods: An observational study with cross-sectional design with consecutive sampling technique was conducted in July–October 2018. All SpA patients who fulfilled the inclusion criteria were included in this study. Data analysis was performed with SPSS v21.0. Results: There were 33 SpA patients (10 males and 23 females) included in this study. The average age was 48.18±12.27 years-old. The average mSASSS score was 24,36 (K:0.93, p:0.00). Metabolic syndrome was diagnosed in 54.5% patients with 100% patients had central obesity, 66.7% had increased blood pressure, 61.5% had impaired fasting glucose, 55.6% had increased triglycerides, and 77.8% had decreased high-density lipoprotein cholesterol. Positive correlation between mSASSS score and metabolic syndrome was observed (r:0.510, p:0.002). Conclusion: A correlation between SpA disease activity measured with mSASSS score and metabolic syndrome was observed. Therefore, routine metabolic syndrome screening is strongly suggested for SpA patients.
AB - Background: Cardiovascular complication remains the long-term complications in spondyloarthritis (SpA). Previous studies revealed that metabolic syndrome is the risk factor of cardiovascular in SpA patients. Previous studies also revealed that the prevalence of the metabolic syndrome is 34.9– 45.7% in SpA patients. However, previous studies also revealed the controversy of the correlation of SpA’ disease activity with metabolic syndrome. Aim: The aim of the study was to investigate the correlation of SpA’ radiographical damage measured with a modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) score with metabolic syndrome in SpA patients, which routinely visited Rheumatology Outpatient Department in Dr. Soetomo General Hospital. Methods: An observational study with cross-sectional design with consecutive sampling technique was conducted in July–October 2018. All SpA patients who fulfilled the inclusion criteria were included in this study. Data analysis was performed with SPSS v21.0. Results: There were 33 SpA patients (10 males and 23 females) included in this study. The average age was 48.18±12.27 years-old. The average mSASSS score was 24,36 (K:0.93, p:0.00). Metabolic syndrome was diagnosed in 54.5% patients with 100% patients had central obesity, 66.7% had increased blood pressure, 61.5% had impaired fasting glucose, 55.6% had increased triglycerides, and 77.8% had decreased high-density lipoprotein cholesterol. Positive correlation between mSASSS score and metabolic syndrome was observed (r:0.510, p:0.002). Conclusion: A correlation between SpA disease activity measured with mSASSS score and metabolic syndrome was observed. Therefore, routine metabolic syndrome screening is strongly suggested for SpA patients.
KW - Metabolic syndrome
KW - Modified stoke ankylosing spondylitis spinal score
KW - Spondyloarthritis
UR - http://www.scopus.com/inward/record.url?scp=85073537012&partnerID=8YFLogxK
U2 - 10.22159/ijap.2019.v11s5.T0049
DO - 10.22159/ijap.2019.v11s5.T0049
M3 - Article
AN - SCOPUS:85073537012
SN - 0975-7058
VL - 11
SP - 56
EP - 60
JO - International Journal of Applied Pharmaceutics
JF - International Journal of Applied Pharmaceutics
IS - Special Issue 5
ER -